WALTHAM, Mass.--(BUSINESS WIRE)--N-of-One, Inc., a leading provider of molecular interpretation and therapeutic strategies for personalized cancer care, today announced that global life sciences company Life Technologies (NASDAQ: LIFE) has selected N-of-One to provide a new type of benefit to its approximately 10,000 employees. For the first time, Life Technologies employees will have confidential access to personalized cancer treatment strategies as an employee benefit, including review of the most advanced treatment options available. N-of-One develops comprehensive molecular diagnostic strategies for physicians and their patients, and based on the findings of the testing, prepares comprehensive treatment reports outlining the therapeutic options available to the patients and their oncologists. The financial terms of the agreement are not disclosed.
Dr. Paul R. Billings, Chief Medical Officer of Life Technologies, said: “Life Technologies is committed to offering the best solutions in personalized medicine. We are proud to make this new and valuable service available to our employees with cancer around the world. N-of-One is the clinical interpretation leader in personalized cancer care and a natural choice as a partner, having delivered thousands of personalized treatment and diagnostic strategy roadmaps to cancer patients and oncologists.”
“We applaud Life Technologies for taking this important and innovative step to give employees access to the most current personalized cancer medicine diagnostic and treatment options available through this innovative benefit offering,” said Christine Cournoyer, Chief Executive Officer of N-of-One. “N-of-One has provided interpretation of patients’ molecular profiling for personalized cancer care diagnostic and treatment strategies through three channels: directly to physicians and patients, through agreements with hospitals and provider networks, and through partnerships to provide interpretation services for leading diagnostic companies.”
Under the terms of the agreement, Life Technologies employees can apply confidentially to work directly with N-of-One. The N-of-One team will coordinate genomic profiling of the cancer, interpretation of the diagnostic results, and development of a comprehensive Treatment Strategy RoadmapTM within a few weeks – all at no cost to the employee. This personalized interpretation and synthesis includes the latest knowledge on cancer treatment options, both approved and in clinical trials, all specifically targeted to each patient’s genetic tumor profile.
“Life Technologies plays a leading role in the evolution of personalized medicine being made possible by genetic sequencing and other advancements,” said Pete Leddy, head of Global Human Resources for Life Technologies. “IMPACT gives our employees access to the same cutting-edge discoveries we are helping create in partnership with pharmaceutical and other IVD companies, and shows we’re willing to walk the walk when it comes to living our values and aligning to our purpose of shaping discovery and improving life.”
“N-of-One supports the physician with the latest knowledge regarding possible treatment options for the patient’s specific cancer diagnosis,” said Jennifer Levin Carter MD, MPH, founder and Chief Medical Officer of N-of-One. “Having these insights can make a difference; in almost 40% of the cases where N-of-One provided personalized treatment and diagnostic strategy roadmaps, the physician chose to make an immediate change to the cancer patient’s treatment strategy.
“With Life Technologies, we have created an innovative new way to give cancer patients access to personalized medicine that can help their oncologists select the most effective treatment options available today – through a benefits program provided by their employer,” Levin Carter continued. “N-of-One, based on our five years of experience, has mastered the ability to deliver meaningful clinical insights from molecular diagnostics to physicians and their patients in an efficient and cost effective manner.”
About Life Technologies
Life Technologies Corporation is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents and licenses that span the entire biological spectrum – scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012.
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
About N-of-One
N-of-One, a leader in precision medicine, leverages its world-class team of experts to translate molecular data specific to each patient into state-of-the-art, clinically actionable insights and therapeutic options focused on the point of care. Using the company’s PrecisionWorks™ knowledge integration platform and framework, N-of-One’s team of experts has delivered thousands of personalized, interpretative roadmaps to oncologists and patients worldwide, either directly to or through employee access benefit programs (such as Life Technologies), through agreements with provider networks (such as Fox Chase Cancer Center in Philadelphia) or through partnerships to provide interpretation services for leading diagnostic companies (such as Foundation Medicine and Clarient). N-of-One does not provide medical advice or promote any product or service. For more information, please visit www.n-of-one.com or call 617-202-9808.
